ACR’s request comes amid ongoing trade wars and new tariffs placed on imaging products. 

Paris, France-based Chipiron will use the Series A financing to build a prototype of its portable machine, hoping to launch clinical trials in 2026.

The declaration comes with the North Billerica, Massachusetts-based drugmaker announcing positive results from two “pivotal” studies of MK-6240. 

Overpromising AI capabilities to hospital stakeholders—now there’s a mistake healthcare AI enthusiasts have been known to make.

Local investigative reporters have uncovered details on a scheme in which patients housed at a seedy motel received treatment for drug abuse as part of a massive Medicare fraud operation. 

In a new report, the AHA said strains from President Trump’s tariffs and struggles with Medicare Advantage plans are creating “financial headwinds” that could shake the economic stability of hospitals nationwide. 

The newly approved device can be worn for up to a week at a time, with no daily maintenance required, and includes advanced AI algorithms that minimize the risk of false alarms or inappropriate shocks.

The company cited declining enrollment as the reason for exiting the exchanges, including from patients seeking Medicare options.